Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.

2024 Evolution of ADA Guidelines

The American Diabetes Association (ADA) emphasizes the use of GLP-1 and GIP/GLP-1 receptor agonists in patients with type 2 diabetes who would benefit from weight and glycemic lowering benefits.  As the ADA guidelines have evolved, GLP-1 RA or GIP/GLP-1 RAs have been suggested earlier in treatment. With an update to the 2024 type 2 diabetes diagnostic criteria, ProAct will be updating its clinical criteria for clients with the standard prior authorization offering in place for patients new to therapy:

Submission of two abnormal screening test results (A1C ≥6.5%; fasting plasma glucose [FPG] ≥126 mg/dL, 2-hour plasma glucose [2hPG] ≥200 mg/dL, per the 2024 T2D diagnostic criteria; and

The above will be added to the criteria requiring a trial and failure to a metformin-containing drug therapy, unless patients with diabetes have documentation of comorbidities, which require treatment with a GLP-1 RA or a GIP/GLP-1 RA or a contraindication.

Documentation of random plasma glucose ≥200 mg/dL in an individual with classic symptoms of hyperglycemia or hyperglycemic crisis, measured either at the same time or at two different time points.

2024 Evolution of ADA Guidelines hero image
ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image